ÂÜÀòÂÒÂ×

Henrik Troest has a diverse work experience spanning over several years. Henrik started their career as a Student at Carlsberg Laboratory, where they conducted research for their MSc in Pharmacy. After that, they worked as a Clinical Monitor at Wellcome A/S, conducting and monitoring clinical studies in Denmark. Henrik then joined GlaxoWellcome as a CRA, responsible for conducting clinical studies in Denmark within the CNS area.

Following this, Henrik Troest worked at H. Lundbeck in various roles. Henrik began as a Clinical Research Manager Trainee and then became a Clinical Research Manager, where they wrote protocols and study reports within the psychiatry field. Henrik later served as a Project Manager, leading core development teams for projects related to schizophrenia. Henrik also took on the role of Product Director, overseeing the launch of the drug Circadin. In their subsequent position as Senior Project Director and Senior Director & Chief Project Director, Henrik's responsibilities included risk management, training, and leading projects related to Selincro and clobazam.

Henrik joined H. Lundbeck's Corporate Project Management R&D division as a Senior Director in 2014. During this time, they implemented several improvements to the Research department's operations and mentored Research Program Leaders. In 2018, they transitioned to H. Lundbeck's R&D Project Management division as a Senior Director, where they led a program team and contributed to the due diligence and integration efforts after the acquisition of Abide Pharmaceuticals.

In 2020, Henrik Troest joined UNION therapeutics A/S as a Project Director, leading a team focused on accelerating an intranasal and inhalation treatment program for COVID-19 patients. Henrik achieved significant milestones in this role, including the formulation of niclosamide and the completion of a phase I SAD/MAD study.

In 2021, Henrik held multiple roles concurrently. Henrik served as a Senior Consultant at BioZeNergy Consulting, providing senior-level consulting services. Henrik also took on the role of Senior Project Leader at Bavarian Nordic. Additionally, they worked as a Project Director at Cessatech A/S, overseeing project activities and focusing on biotech challenges.

Henrik Troest has a diverse education history. Henrik earned a Master's Degree in Molecular biology and NMR from Danmarks Farmaceutiske Universitet from 1987 to 1993. In 1983 to 1985, they obtained a Master of Science (M.Sc.) in Chemistry from Københavns Universitet - University of Copenhagen. Before that, they completed their high school education at Tårnby Gymnasium from 1980 to 1983, where they studied Mathematics, biology, chemistry, and physics. Henrik also attended St Magleby school from 1970 to 1980 for their primary education but did not receive a degree as public schools in Denmark do not grant degrees.

In terms of additional certifications, Henrik became an NLP Business Practitioner through Michael Kold NLP Europe in 2011. Henrik also completed a diploma in MMPI (Managing Medical Product Innovation) from Copenhagen Business School in 2007. Later in their career, they pursued further education in Effective strategic leadership through positive psychology at Copenhagen Business School in 2014.

It is worth mentioning that no information is provided about Henrik Troest's obtained year or institution for the NLP Business Practitioner certification, and no start or end year is provided for their PharmD degree in Molecular Biology at IT-Universitetet i København.